The global acute repetitive seizures (ARS) market is gaining momentum as advancements in neurological treatments, greater awareness of epilepsy-related disorders, and improved drug development pipelines drive demand for effective therapies. Valued at USD 2.90 billion in 2023, the market is expected to expand steadily at a compound annual growth rate (CAGR) of...